tiprankstipranks
Dermata Therapeutics (DRMA)
NASDAQ:DRMA
US Market
Holding DRMA?
Track your performance easily

Dermata Therapeutics (DRMA) Income Statement

113 Followers

Dermata Therapeutics Income Statement

Last quarter (Q2 2024), Dermata Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Dermata Therapeutics's net income was $-2.83M. See Dermata Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 6.90M---$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
$ 6.90M-----
Operating Expense
$ 10.12M$ 8.04M$ 9.67M$ 7.86M$ 3.17M$ 4.47M
Operating Income
$ -10.12M$ -8.04M$ -9.67M$ -7.86M$ -3.17M$ -4.47M
Net Non Operating Interest Income Expense
$ 302.56K$ 247.22K$ 63.57K$ -45.61K$ -197.27K$ -250.75K
Other Income Expense
----$ 133.59K-
Pretax Income
$ -9.82M$ -7.79M$ -9.61M$ -7.90M$ -3.24M$ -4.72M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -9.82M$ -7.79M$ -9.61M$ -10.46M$ -3.24M$ -4.72M
Basic EPS
$ -11.00$ -2.67$ -208.80$ -583.20$ -0.39$ -0.57
Diluted EPS
$ -11.00$ -2.67$ -208.80$ -583.20$ -0.39$ -0.57
Basic Average Shares
$ 7.99M$ 2.92M$ 46.03K$ 17.93K$ 8.33M$ 8.33M
Diluted Average Shares
$ 7.99M$ 2.92M$ 46.03K$ 17.93K$ 8.33M$ 8.33M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 10.12M$ 8.04M$ 9.67M$ 7.86M$ 3.17M$ 4.47M
Net Income From Continuing And Discontinued Operation
$ -9.82M$ -7.79M$ -9.61M$ -7.90M$ -3.24M$ -4.72M
Normalized Income
$ -4.49M$ -6.16M--$ -3.37M$ -4.72M
Interest Expense
----$ 197.27K$ 250.75K
EBIT
$ -10.00M$ -8.04M$ -9.67M$ -7.86M$ -3.04M$ -4.47M
EBITDA
$ -10.00M$ -8.04M$ -9.67M$ -7.84M$ -3.04M$ -4.47M
Currency in USD

Dermata Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis